Literature DB >> 11545642

Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study.

R Klein1, B E Klein, S C Jensen, K J Cruickshanks, K E Lee, L G Danforth, S C Tomany.   

Abstract

OBJECTIVE: To evaluate incident early age-related maculopathy (ARM) after a 5-year interval with respect to medication use.
DESIGN: Population-based incidence study.
SETTING: Participants were adults aged 43 to 86 years living in Beaver Dam, Wis, when first examined in 1988-1990 (n = 4926); they were reexamined in 1993-1995 (n = 3684).
METHODS: All participants were examined and interviewed and stereoscopic color fundus photographs were taken. All procedures were done by standard protocol at both examinations. Incidence of ARM was based on grading using the Wisconsin ARM Grading System. All prescribed and over-the-counter medications in current use were brought to the examination site and the names were recorded at that time.
RESULTS: There were 678 drug preparations (active ingredients) being used at the baseline examination. No relations were found between most antihypertensive drugs, most central nervous system medications, aspirin and other nonsteroidal anti-inflammatory agents, estrogens, lipid-lowering agents, and incident early ARM over the 5-year period. Age- and sex-adjusted logistic regression analyses suggested possible associations (P<.10) between the use of phenothiazine antidopaminergics (odds ratio [OR], 2.83; 95% confidence interval [CI], 0.97-8.23; P =.06), desiccated thyroid hormones (OR, 2.32; 95% CI, 0.89-6.07; P =.09), and calcium channel blockers (OR, 1.70; 95% CI, 0.93-3.12; P =.08) with incident ARM. When additional information on past use was included in the regression model, the association remained for calcium channel blockers, but not for phenothiazines and desiccated thyroid hormones. A lower incidence of early ARM occurred in those who took antidepressants (OR, 0.34; 95% CI, 0.12-0.94; P =.04) at the baseline examination.
CONCLUSION: Although many different medications were being used at the baseline examination in the Beaver Dam Eye Study cohort, there were no striking associations with the 5-year incidence of early ARM.

Entities:  

Mesh:

Year:  2001        PMID: 11545642     DOI: 10.1001/archopht.119.9.1354

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  34 in total

1.  The association between statin use and age related maculopathy.

Authors:  G McGwin; C Owsley; C A Curcio; R J Crain
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  Associations of selected medications and visual function: the Beaver Dam Eye Study.

Authors:  B E K Klein; R Klein; M D Knudtson; K E Lee; L G Danforth; J O Reinke; A M Adler
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

3.  Dissection of chromosome 16p12 linkage peak suggests a possible role for CACNG3 variants in age-related macular degeneration susceptibility.

Authors:  Kylee L Spencer; Lana M Olson; Nathalie Schnetz-Boutaud; Paul Gallins; Gaofeng Wang; William K Scott; Anita Agarwal; Johanna Jakobsdottir; Yvette Conley; Daniel E Weeks; Michael B Gorin; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-28       Impact factor: 4.799

4.  The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study.

Authors:  G McGwin; T A Hall; A Xie; C Owsley
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

Review 5.  Role of Lipids in Retinal Vascular and Macular Disorders.

Authors:  Gunjan Prakash; Rachit Agrawal; Tanie Natung
Journal:  Indian J Clin Biochem       Date:  2016-03-08

6.  Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.

Authors:  William G Christen; Robert J Glynn; Emily Y Chew; Julie E Buring
Journal:  Ophthalmology       Date:  2009-10-07       Impact factor: 12.079

Review 7.  Statins for age-related macular degeneration.

Authors:  Peter Gehlbach; Tianjing Li; Elham Hatef
Journal:  Cochrane Database Syst Rev       Date:  2015-02-11

8.  SYSTEMIC BETA-BLOCKERS AND RISK OF PROGRESSION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Authors:  Anton M Kolomeyer; Maureen G Maguire; Wei Pan; Brian L VanderBeek
Journal:  Retina       Date:  2019-05       Impact factor: 4.256

9.  Statin use and the five-year incidence and progression of age-related macular degeneration.

Authors:  Ronald Klein; Michael D Knudtson; Barbara E K Klein
Journal:  Am J Ophthalmol       Date:  2007-05-02       Impact factor: 5.258

10.  Risk factors for age-related maculopathy.

Authors:  Paul P Connell; Pearse A Keane; Evelyn C O'Neill; Rasha W Altaie; Edward Loane; Kumari Neelam; John M Nolan; Stephen Beatty
Journal:  J Ophthalmol       Date:  2009-09-06       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.